| Type |
Other Meetings |
| Title |
CANCELLED - A Journey into Influenza Antigenic Space Using Systems Serology |
| Date |
Friday, June 21, 2019 |
| Time |
11:00 a.m. - 12:00 p.m. |
| Location |
305 WRB |
| Speaker(s) |
Tomer Hertz, Ph.D., head, Laboratory of Systems Immunology, Ben-Gurion University of the Negev |
| Speaker Bio |
Tomer Hertz received his Ph.D. in computational neuroscience from the Hebrew University in the field of machine learning and pattern recognition. His then joined Microsoft Research as a potdoctoral student in computational immunology focusing on developing and applying algorithms for MHC-peptide binding and also for HLA supertype classification. He then joined the Fred Hutch Cancer Research Center where he has been a faculty member in the vaccine and infectious disease division for seven years focusing on immunological research in both Influenza and HIV as disease models. In 2014, he joined the department of immunology at Ben-Gurion University of the Negev in Israel where he heads a systems immunology lab that studies the role of immune history and its effect on vaccination and natural infection, modeling peptide:MHC:TCR interactions, and novel methods for the analysis of high-dimensional immunological data.
|
| Open To |
Public |
| Contact |
Inna Ricardo-Lax |
| Phone |
917-251-5403 |
| Notes |
Vaccination is an effective tool for preventing influenza infection. A variety of factors have been shown to impact the observed heterogeneity and inter-individual variations in immune responses following vaccination including age, gender, ethnicity and immunological history (the individual's memory antibody repertoire to previously encountered pathogens and vaccines). Throughout life individuals are infected by and vaccinated with multiple influenza strains and develop a broad and diverse influenza Ab repertoire. We have been developing a novel low-volume antigen microarray assay for profiling influenza immunological history, and used it to assess the effects of immune history on vaccine-induced immunogenicity and protection, using samples from an influenza vaccine efficacy trial, as well as to characterize the maternal fetal transfer of influenza specific antibodies. |
